Clinical trials: Age Related Maculopathy
Age-Related Macular Degeneration
A Study to Compare SB11 (Proposed Ranibizumab Biosimilar) to Lucentis in Subjects With Neovascular Age-related Macular Degeneration (AMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy, safety, pharmacokinetics and immunogenicity of SB11 compared to Lucentis® in subjects with neovascular AMD.
- Trial name
- NCT03150589
- Testing
- SB11 (Proposed ranibizumab biosimilar), Lucentis (ranibizumab)
- Where
- 75 sites in United States, Czechia and 7 more
- Volunteers
- 705 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Cataract, AMD - Age-Related Macular Degeneration
Safety and Clinical Performance of the LENTIS® MAX LS-313 MF80 Compared With the Monofocal L-313 in Cataract Patients With Late Age-Related Macular Degeneration: A Multicenter Comparative Clinical Investigation.
The goal of this clinical trial is to evaluate the safety, visual performance, and potential clinical benefits of the LENTIS® MAX LS-313 MF80 intraocular lens compared with the monofocal LENTIS® L-313 intraocular lens in adult…
- Trial name
- NCT07915076
- Testing
- Intraocular Lens
- Volunteers
- 35 people
- Sponsor
- Teleon Surgical B.V.
Neovascular Age-related Macular Degeneration
Faricimab for High-frequent Aflibercept Treated Neovascular Age-related Macular Degeneration
Study purpose: To evaluate if previously high-frequent (3-5 weekly) aflibercept treated neovascular age-related macular degeneration (nAMD) can be extended in their treatment interval when switched to faricimab.
- Trial name
- FAN (NCT05941715)
- Testing
- Aflibercept 40 MG/ML, Faricimab 120 MG/ML
- Where
- Austria
- Volunteers
- 70 people
- Sponsor
- Medical University of Graz
Neovascular (Wet) Age-related Macular Degeneration
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
Researchers are looking for a better way to treat people who have neovascular (wet) age-related macular degeneration (nAMD or wet AMD).
- Trial name
- XPAND (NCT05473715)
- Testing
- Aflibercept(BAY86-5321, Eylea)
- Where
- 3 sites in Canada, United Kingdom
- Volunteers
- 3 people
- Sponsor
- Bayer
Age Related Macular Degeneration
PDT Study for Exudative AMD With PCV
The purpose of this study is to evaluate and conduct an exploratory comparison of the efficacy and safety of indocyanine green angiography (ICGA) guided photodynamic therapy (PDT) and fluorescein angiography (FA) guided PDT for…
- Trial name
- NCT00331435
- Testing
- Ocular photodynamic therapy with verteporfin
- Where
- 17 sites in Japan
- Volunteers
- 113 people
- Sponsor
- Ophthalmic PDT Study Group
Neovascular Age-related Macular Degeneration
Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)
The study evaluated the efficacy and safety of two different dosing regimens of ranibizumab (either monthly injections or injections as-needed based on the stability of a patient's vision) in Chinese patients with wet age-related…
- Trial name
- DRAGON (NCT01775124)
- Testing
- Ranibizumab
- Where
- 23 sites in China
- Volunteers
- 332 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration
Telemedicine in Age-Related Macular Degeneration
This study seeks to evaluate a system for the automated early detection of Age-Related Macular Degeneration (AMD). AMD is a condition in which there is breakdown of the macula of the eye, the part of the retina that is…
- Trial name
- NCT04863391
- Testing
- Referrable versus Non Referral AMD diagnostic test
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- The New York Eye & Ear Infirmary
Age Related Macular Degeneration, Stargardt's Disease
Stem Cell Therapy for Outer Retinal Degenerations
This study is a Phase I/II , open label,non randomized, prospective study to determine the safety of human embryonic stem cell derived Retinal pigmented epithelium (hESC RPE) sub retinal injections versus hESC RPE seeded on a…
- Conditions
- Age Related Macular Degeneration, Stargardt's Disease, Exudative Age-related Macular Degeneration
- Trial name
- NCT02903576
- Testing
- injection of hESC-RPE in suspension, injection hESC-RPE seeded in a substrate
- Where
- Brazil
- Volunteers
- 15 people
- Sponsor
- Federal University of São Paulo
Age-Related Macular Degeneration
Effect of Squalamine Lactate Ophthalmic Solution, 0.2% in Subjects With Neovascular Age-Related Macular Degeneration
The purpose of this study is to evaluate anatomical and functional effect of combination therapy of Squalamine Lactate Ophthalmic Solution, 0.2% administered twice daily with monthly ranibizumab intravitreal injections in…
- Trial name
- NCT02511613
- Testing
- Squalamine Lactate Ophthalmic Solution, 0.2%, ranibizumab
- Where
- 4 sites in United States
- Sponsor
- Ohr Pharmaceutical Inc.
Choroidal Neovascularization, Mineralocorticoid Excess
Biomarkers and Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
- Trial name
- BioNéoRet (NCT04439708)
- Testing
- Blood and aqueous humor biomarker of treatment response
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
DME, Retinal Vein Occlusion (RVO)
AI vs. Physician for Anti-VEGF Decision-Making: An RCT
We developed an artificial intelligence system, called QiLin, which was designed to assist anti-VEGF treatment decisions in retinal diseases.
- Conditions
- DME, Retinal Vein Occlusion (RVO), Neovascular (Wet) Age-Related Macular Degeneration
- Trial name
- NCT07328776
- Testing
- QiLin-assisted, physician only, without QiLin assisted
- Where
- 2 sites in China
- Volunteers
- 200 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Age-Related Macular Degeneration, Eye Diseases
Blood and Saliva Sample Collection for AREDS 2
Background: The Age-Related Eye Disease Study 2 (AREDS 2) is looking at different eye diseases. Study participants will provide blood and saliva samples. The samples will be stored for research on eye diseases.
- Trial name
- NCT01553474
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Eye Institute (NEI)
Neovascular Age-related Macular Degeneration
Neovascular Age-related Macular Degeneration
Age-related macular degeneration (AMD) is the leading cause of blindness in non-Hispanic white Americans. Neovascular AMD is an advanced form of macular degeneration that historically has accounted for the majority of vision loss…
- Trial name
- NVAMD (NCT01712035)
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- Oregon Health and Science University
Retinal Vasculitis
A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)
This study will describe and estimate the incidence of RV events among patients and patient eyes receiving aflibercept intravitreal (IVT) (Eylea® 2mg) therapy in US clinical practice.
- Trial name
- NCT06769412
- Testing
- aflibercept 2 mg
- Where
- United States
- Volunteers
- 550,000 people
- Sponsor
- Regeneron Pharmaceuticals
Dry AMD
Morpho-functional Changes After Oral Supplementation of Antioxidants and Anti-inflammatory Treatment in Age-Related Macular Degeneration.
In patients with AMD a deterioration of the antioxidant mechanisms of the retina is observed and therefore an increase in the production of free radicals responsible for tissue damage.
- Trial name
- MACUPREV (NCT03919019)
- Testing
- Macuprev Group
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
nAMD, DME
Real-World Study of Intravitreal Aflibercept 8 mg in Pretreated Eyes With nAMD or DME
The goal of this multicentre observational study is to evaluate the interval-extension potential, effectiveness, and safety of intravitreal aflibercept 8 mg in pretreated eyes with neovascular age-related macular degeneration…
- Trial name
- ALLEVI8 (NCT07761039)
- Testing
- Aflibercept 8mg
- Volunteers
- 100 people
- Sponsor
- Grupo de Estudos da Retina
Age-Related Macular Degeneration
Photodynamic Therapy in Occult-Only Lesions (POOL)
Age related macular degeneration is the leading cause of blindness for people over 50 in the western world. Blood vessels which start to grow form a lesion in the back of the eye.
- Trial name
- NCT00135837
- Testing
- Verteporfin for injection
- Where
- Switzerland
- Volunteers
- 202 people
- Sponsor
- Novartis
Macular Degeneration, Age-related, Geographic Atrophy
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to people 50 years or older with an eye condition called geographic atrophy. The purpose of this study is to compare a medicine called BI 771716 with a medicine called pegcetacoplan.
- Trial name
- VERDANT (NCT06722157)
- Testing
- BI 771716, Pegcetacoplan
- Where
- 46 sites in United States
- Volunteers
- 202 people
- Sponsor
- Boehringer Ingelheim
Choroid Neovascularization, Age-Related Macular Degeneration
A Study Using Intravitreal Injections of a Small Interfering RNA in Patients With Age-Related Macular Degeneration
This is a 24-month study to evaluate multiple doses of AGN211745 (previously known as Sirna-027) in treatment of subfoveal choroidal neovascularization associated with age-related macular degeneration
- Trial name
- NCT00395057
- Testing
- AGN 211745, Ranibizumab 500µg
- Where
- 3 sites in United States, Australia and 1 more
- Volunteers
- 138 people
- Sponsor
- Allergan
Age Related Macular Degeneration
A Study of the NeoVista Ophthalmic System for the Treatment of Subfoveal CNV Associated With Wet AMD in Patients That Require Persistent Anti-VEGF Therapy
The objective of the MERITAGE Trial is to evaluate the safety and efficacy of focal delivery of radiation for the treatment of subfoveal choroidal neovascularization (CNV) associated with wet age-related macular degeneration…
- Trial name
- MERITAGE (NCT00809419)
- Testing
- NeoVista Ophthalmic System
- Where
- 5 sites in United States, Israel and 1 more
- Volunteers
- 32 people
- Sponsor
- NeoVista
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.